Undifferentiated pleomorphic sarcoma of bone (UPSb) is a rare primary bone sarcoma that lacks a specific line of differentiation. There is very little information about the genetic alterations leading to tumourigenesis or malignant transformation. Distinguishing between UPSb and other malignant bone sarcomas, including dedifferentiated chondrosarcoma and osteosarcoma, can be challenging due to overlapping features. To explore the genomic and transcriptomic landscape of UPSb tumours, whole-exome sequencing (WES) and RNA sequencing (RNA-Seq) were performed on UPSb tumours. All tumours lacked hotspot mutations in IDH1/2 132 or 172 codons, thereby excluding the diagnosis of dedifferentiated chondrosarcoma. Recurrent somatic mutations in TP53 were identified in four of 14 samples (29%). Moreover, recurrent mutations in histone chromatin remodelling genes, including H3F3A, ATRX and DOT1L, were identified in five of 14 samples (36%), highlighting the potential role of deregulated chromatin remodelling pathways in UPSb tumourigenesis. The majority of recurrent mutations in chromatin remodelling genes identified here are reported in COSMIC, including the H3F3A G34 and K36 hotspot residues. Copy number alteration analysis identified gains and losses in genes that have been previously altered in UPSb or UPS of soft tissue. Eight somatic gene fusions were identified by RNA-Seq, two of which, CLTC-VMP1 and FARP1-STK24, were reported previously in multiple cancers. Five gene fusions were genomically characterised. Hierarchical clustering analysis, using RNA-Seq data, distinctly clustered UPSb tumours from osteosarcoma and other sarcomas, thus molecularly distinguishing UPSb from other sarcomas. RNA-Seq expression profiling analysis and quantitative reverse transcription-polymerase chain reaction showed an elevated expression in FGF23, which can be a potential molecular biomarker for UPSb. To our knowledge, this study represents the first comprehensive WES and RNA-Seq analysis of UPSb tumours revealing novel protein-coding recurrent gene mutations, gene fusions and identifying a potential UPSb molecular biomarker, thereby broadening the understanding of the pathogenic mechanisms and highlighting the possibility of developing novel targeted therapeutics.
Introduction
Undifferentiated high-grade pleomorphic sarcoma of bone (UPSb) is a rare aggressive bone sarcoma that lacks a specific line or pattern of differentiation [1] . These tumours represent <2% of all primary malignant bone neoplasms and rarely occur in young adults [1, 2] . Tumours commonly arise in long bones of lower extremities, particularly the femur, followed by tibia and humerus, with a metastatic rate of at least 50%, especially to lungs [2, 3] . The morphological appearance of the tumours is heterogeneous, consisting of atypical spindle and pleomorphic cells that lack matrix production. As UPSb is a diagnosis exclusion, thorough and Genetic alterations landscape in UPSb tumours 167 extensive sampling of the tumour to rule out osteosarcoma or dedifferentiated chondrosarcoma is mandatory [4] . This might pose diagnostic difficulties, particularly in a limited biopsy sample. The recommended treatment generally involves neoadjuvant therapy followed by wide surgical excision [5] . The chemosensitivity and survival rate of UPSb are similar to osteosarcoma but distinction from dedifferentiated chondrosarcoma, which has a dismal prognosis, is important [5] . To date, there are no molecular studies or stringent diagnostic criteria to distinguish between these bone sarcomas. The genetics of UPSb is poorly understood. Previous studies have reported low frequency of TP53 mutations, MDM2 amplification [6] and various genomic gains and losses, including CDKN2A, RB1 and TP53 [2] . Nevertheless, no extensive high-throughput studies have been conducted to achieve a comprehensive understanding of the aetiology of these tumours. To gain further comprehensive insights into the molecular landscape and pathogenic mechanisms of UPSb, we performed integrative analyses using whole-exome sequencing (WES) and RNA sequencing (RNA-Seq).
Materials and methods

Tumour samples
A retrospective search of the pathology database at the Royal Orthopaedic Hospital for resected samples of UPSb was carried out. All samples were obtained from the Royal Orthopaedic Hospital NHS Foundation Trust Tumour Bank with informed consent from the patient and ethical approval from institutional and local research committee boards. Prior to the study, all patient samples were anonymised and used in alliance with the ethical rules and regulations presented in the Declaration of Helsinki. In total, 14 cases with the diagnosis of UPSb were identified (additional details are provided in supplementary material, Supplementary materials and methods).
WES and copy number alteration analysis
DNA from fresh frozen and formalin-fixed paraffin-embedded (10 × 10 μm sections) tissues was extracted and purified using the DNA Isolation (Roche Diagnostic, Burgess Hill, UK) and Arcturus PicoPure DNA Extraction kits (ThermoFisher Scientific, Gloucester, UK), respectively, following the manufacturers' instructions. A total of 1-3 μg of DNA from 12 tumours and nine corresponding normal tissues were sent to Oxford Gene Technology (Oxford, UK) for WES. Exons were captured using the Agilent SureSelect Human All Exon V5 kit (Agilent, Santa Clara, CA, USA), following the manufacturer's protocol, and were massively sequenced using either the Illumina HiSeq 2000 (100 bp paired-end) or NextSeq500 (150 bp paired-end) platforms (Illumina, San Diego, CA, USA). Two tumours and one corresponding normal sample were exome-sequenced at SMCL Next Generation Sequencing Hub (Cambridge, UK). Exons were captured by Illumina Nextera Rapid Capture Exome kit and sequenced using Illumina HiSeq 4000, generating 2 × 150 bp reads. Additional details are provided in supplementary material, Supplementary materials and methods.
Copy number variation (CNV) analysis (from WES data) was performed on 10 normal-paired UPSb tumours using the CNVkit (San Francisco, CA, USA), applying the tool's default settings (https://cnvkit.readthedocs.io/ en/stable/).
RNA-Seq experiment
Total RNA from eight fresh frozen tissues was extracted using either the standard TRIzol-chloroform method or the Qiagen RNeasy Mini kit (Qiagen, Manchester, UK) following the manufacturers' instructions. The quality and concentration of RNA was assessed using an Agilent 2100 bioanalyser. A total of 50-100 ng DNase-treated RNA from each tumour was massively sequenced at the Genomics Birmingham facility (Institute of Cancer and Genomic Sciences, University of Birmingham, Birmingham, UK). Additional details are provided in supplementary material, Supplementary materials and methods.
RNA-Seq differential gene expression profiling and hierarchical clustering analyses
The 149 RNA-Seq samples from the CINSARC dataset [7] were retrieved from the Sequence Read Archive Bioproject PRJNA282597 (https://trace.ncbi .nlm.nih.gov/Traces/sra/sra.cgi?study=SRP057793) and 16 osteosarcoma samples were randomly chosen from the SRA bioproject PRJNA345424 (https://trace.ncbi.nlm.nih.gov/Traces/sra/sra.cgi? study=SRP090849) [8] . Gene expression values were extracted using Kallisto v0.42.5 [9] with the GRCh38 release 79 genome annotation and transformed into log 2 (tpm + 2) prior to sample aggregation and normalisation using the quantile method of the limma R package, within the R version 3.1.2 [10] . Clustering was computed using the Cluster v2.0.3 package. Pairwise comparisons of expression profiles were performed using F-test variance comparison prior to Student's t-test statistics with a Bonferroni correction. For each tumor group containing more than 20 samples, pairwise comparison with UPSb was repeated 20 times with random sampling of 10 samples among this group. Gene ontology analyses were performed with DAVID v6.7 [11] . Figure S1 ). This overall somatic mutation burden is comparable with a low mutation burden average of 1.06 per megabase identified in 206 soft-tissue sarcomas, including 44 UPS of soft tissue (UPSst) [12] . Somatic SNVs comprised of: 748 nonsynonymous substitutions, 33 nonsense and 13 splice sites mutations. A total of 123 SNVs and indels were validated by Sanger sequencing, achieving a 96.6% validation rate. To identify potential cancer driver genes, we focused on somatic recurrent genes that were found to be mutated in more than one tumour. A total of 31 recurrent genes harbouring heterozygous somatic mutations were identified in two of 14 (14%) tumours, except for TP53, which was mutated in four of 14 (29%) samples ( Figures 1A, 2A ). The majority of recurrent genes were confirmed by Sanger sequencing (examples can be found in supplementary material, Figure S2 ). All four TP53 somatic missense substitutions (R158H, V216M, Y236C, C242G) are described as 'somatic' in the COSMIC database and predicted to be deleterious by two independent in silico tools (see supplementary material, Table S2 ). The V216 M missense substitution has been reported previously in a UPSb tumour with a progressive disease behaviour [6] . In addition to mutations in the TP53 gene, which participates in the integrity of histone remodelling complexes [13] , recurrent somatic mutations in histone remodelling genes including H3F3A, ATRX and DOT1L were detected in five of 14 (36%) samples, suggesting a potential role of defective chromatin remodelling genes in UPSb tumourigenesis ( Figure 2B -D, see supplementary material, Table S2 ). Somatic G34 V missense substitution and V35_K36insL in-frame insertion in the previously known H3F3A hotspot residues were identified in two UPSb tumours. Mutations in ATRX and DOT1L were missense substitutions. One ATRX mutation, E351V, is reported to be somatic in the COSMIC database. We identified two mutations in DOT1L, G307 V and Q595H occurring in histone-lysine N-methyltransferase catalytic DOT1 domain and STAT1 binding motifs, respectively. To further investigate the cancer-related genes, all recurrent candidate genes were assessed against COSMIC Cancer Gene Census (CCGC) and InTOgen cancer driver genes databases. Seven genes (TP53, ATRX, H3F3A, ZFHX3, CSMD3, PRPRT, TRIO) were classified as cancer drivers ( Figure 1A ). Eight recurrent genes (TP53, ATRX, DOT1L, GCGR, COL4A2, KCNQ3, PKLR, SLC12A1) were identified as potential druggable genes by the drug-gene interaction database (DGIdb) ( Figure 1A ).
Somatic copy number alteration analysis using WES data
Somatic CNV analysis was performed on 10 normalpaired UPSb tumours. Supplementary material, Figure  S3 shows the overall somatic CNV heatmap of UPSb tumours. In comparison with a study by Niini et al [2] , which assessed the CNV profile in UPSb, we identified CNV changes in the following genes: ING1, CGK4, MDM2, MYC, PDGFRA, KIT, KDR, PDGFA, PDGFB, VEGFA (see supplementary material, Table S3 ). We also found somatic CNV losses in RB1 in five of 10 (50%) cases, gains and losses in VGLL3 and CDKN2A, losses in YAP1, as well as loss and gain in CCNE1 (see supplementary material, Table S3 ), genes that had been previously implicated in UPSst [12] .
RNA-Seq identifies two previously reported and six novel gene fusions
RNA-Seq was conducted on eight tumours, achieving a mean of 59 722 616 reads with a 90.07% successful alignment rate to the reference genome. Using two bioinformatic fusion callers and following a series of filtering steps (see Materials and methods), eight gene fusion candidates were identified in four tumours, two of which were previously described in the literature (CLTC-VMP1 and FARP1-STK24) [14, 15] , whereas the remaining fusions are novel ( Figure 1B and see supplementary material, Table S4 ). In addition, the previously reported CTSC-RAB38 read-through chimera in cancer and noncancer tissues [16] was identified in two of eight tumours (25%). Using reverse transcription-polymerase chain reaction (RT-PCR), all eight fusions were detected in the tumour cDNA but not in corresponding normal tissue samples, suggesting that the fusions are highly tumour-specific. Focusing on gene fusions with potential druggability and/or involvement in tumourigenesis, genomic analysis breakpoints using long-range polymerase chain reaction (LR-PCR) were performed on five of the eight fusions to determine the precise genomic breakpoints (see supplementary material, Table S4 ). Using LR-PCR, all five fusions were genomically characterised and validated in the tumour DNA, but were not detected in corresponding normal tissues, confirming the somatic status of the fusions. APOL1-MYH9 and PKNOX2-MMP20 occur as a result of paracentric chromosome inversion, whereas ASAP2-ADAM17 forms by an interstitial chromosomal deletion of ∼97 kb. The two gene fusions previously reported in other cancer samples and cell lines are CLTC-VMP1 and FARP1-STK24 (see supplementary material, Figures S4, S5) . CLTC-VMP1 has been described previously in BT-549 and HCC1954 breast cancer cell lines [14] , hypopharynx tumour [17] and large-cell lung carcinoma [18] . The CLTC-VMP1 gene fusion results from joining the first 14 exons of CLTC to the last two exons of VMP1 (see supplementary material, Figure S4A ,B). Genomic breakpoint analysis revealed a ∼158 kb interstitial deletion within CLTC and VMP1 genes, leading to a complete deletion of PTRH2 gene residing within the fusion gene partners (see supplementary material, Figure S4C,D) . The CLTC-VMP1 chimeric transcript is an out-of-frame fusion, for which the predicted translation product includes the first 764 amino acids of the CLTC gene that extends to the beginning of exon 11 of VMP1 (at codon 324) and reaching a premature stop codon after 75 amino acids ( Figure 3A) . The FARP1-STK24 chimeric fusion is formed as a result of a ∼219 kb interstitial deletion within gene partners, linking the first three and five exons of FARP1 and STK24, respectively (see supplementary material, Figure S5A-D) . The chimeric transcript is in-frame, consisting of the first 88 and 211 amino acid residues of FARP1 and STK24, respectively ( Figure 3B ). In FARP1-STK24, the majority of the STK24 protein kinase domain is retained yet missing the STK24 regulatory region ( Figure 3B ). This gene fusion has been previously described in an invasive breast cancer tumour [15] . To infer the potential biological relevance of the novel chimeric transcripts, gene fusion partner genes were checked against CCGC and the InTOgen database, classifying CLTC and MYH9 (in APOL1-MYH9) as 'cancer driver genes' ( Figure 1B) . DGIdb identified three drug-gene interactions for three fusion partner genes (underlined) in the following gene fusions: FARP1-STK24, ASAP2-ADAM17, PKNOX2-MMP20 ( Figure 1B) .
Hierarchical clustering and expression profiling analyses using RNA-Seq data and UPSb-G2, thus molecularly distinguishing UPSb from osteosarcoma and other sarcomas ( Figure 4A ). Checking the clinicopathological information of the two UPSb groups, UPSb-G2 (T1, T2, T5, T6) primarily has spindle cell morphology, in comparison with UPSb-G1 (T9, T10, T13, T14), which shows a mixture of spindle, pleomorphic and epithelioid morphology (an example of each group can be found in supplementary material, Figure S6 ). Supervised expression analysis of UPSb versus other sarcoma subtypes highlighted FGF23, fibroblast growth factor 23, as a specifically expressed gene in UPSb tumours ( Figure 4B ). David Gene Ontology analyses of specific UPSb genes identified a strong enrichment of immune response genes, suggesting their potential involvement in UPSb tumourigenesis ( Figure 4C ).
Confirmation of elevated FGF23 expression in UPSb using RT-qPCR
To confirm the elevated expression of FGF23 by RNA-Seq, RT-qPCR was carried out on four UPSb tumours and four normal tissue controls. An elevated expression of FGF23 was observed in all tumours, compared with low FGF23 expression levels in normal samples (p = 0.0286, see supplementary material, Figure S7 ).
Discussion
In this study, we examined the somatic genetic alterations present in UPSb tumours using WES and RNA-Seq technologies, as well as comparing transcriptomic profiles of UPSb with other sarcomas. We performed WES on 14 tumours and focused on genes that are altered in more than one tumour, identifying a total of 31 recurrent genes. TP53 was the most frequently mutated gene (29% of tumours). In 36% of the tumours we identified mutations in chromatin remodelling genes (H3F3A, ATRX, DOT1L) that have not been previously described in the UPSb subtype. A significant co-occurrence of the G34 H3F3A mutation with ATRX/DAXX and TP53 mutations has been observed in nearly 100% of glioblastoma tumours [19] . Notably, no correlation of H3F3A mutations was observed in UPSb tumours harbouring TP53, ATRX or DOT1L mutations.
Somatic CNV analysis on 10 tumours revealed alterations in genes that have been previously implicated in UPSb [2] and UPSst [12] , including MDM2, ING1, RB1, CDKN2A, VGLL3, YAP1 and CCNE1. Deep deletions in RB1 and CDKN2A have been identified recently in 16 and 20% of UPSst, respectively; whereas high-level amplifications were present in VGLL3, YAP1 and CCNE1 in 11, 3 and 10% of UPSst [12] .
Heterozygous R132 and R172 hotspot point mutations in IDH1 and IDH2, respectively, are present in 61-87% of chondrosarcoma cases, including dedifferentiated chondrosarcoma [4, 20] ; by contrast, these changes are absent in 222 osteosarcoma samples [21] . In an earlier study, Chen et al [4] investigated the IDH1/2 mutation status in the 14 UPSb tumours used in this study and found no R132 and R172 mutations in any tumour, ruling out a diagnosis of dedifferentiated chondrosarcoma. Unlike the established association of IDH1/2 in chondrosarcoma, the somatic genomic profile of osteosarcoma is complex and involves multiple genes, mainly TP53 and RB1 [22] . These genes are well-known cancer driver genes implicated in multiple cancers and therefore cannot be sensitively used to exclude the diagnosis of osteosarcoma.
The TP53 gene is the most frequently mutated gene in various human cancers and 90% of TP53 mutations are missense changes with potential gain-of-function characteristics [23, 24] . Previously, TP53 mutations were identified in 22% of UPSb tumours by conventional PCR and Sanger sequencing [6] . In this study, using massive-parallel sequencing for the first time on this tumour subtype, four TP53 missense mutations (R158H, COSMIC ID: COSM1640853; V216M, COSM10667; Y236C, COSM10731; C242G, COSM3717645), all occurring in the DNA-binding domain of p53 protein ( Figure 2A) , were identified. Mutations in the p53 DNA-binding domain can reduce the protein's binding specificity to DNA sequence motifs in p53-regulated genes. The R158H, V216 M and Y236C mutations are reported among the 50 most common somatic missense mutations in TP53, highlighting their potential pathological role in tumourigenesis [23] . We could not find significant differences in the total number of mutations in samples harbouring TP53 mutations (n = 4) compared with the remaining samples (n = 10). Correlations between TP53 mutations and clinical implications are difficult to establish due to the clinical heterogeneity of the patients and the small sample size; hence, additional investigations to elucidate their
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H3F3B (K36) were identified in 92% of giant cell tumours of the bone and 95% of chondroblastoma cases, respectively [25] . In this study, we identified recurrent somatic mutations (G34 V, COSM502595 and V35_K36insL, COSM5574356) in H3F3A affecting the previously reported amino acid residues ( Figure 2B ). These hotspot sites are well-conserved amino acid residues of the amino-terminus tail that undergo post-translational modifications [19] . Lysine 36 is a principal methylation site that typically promotes gene transcription when methylated or acetylated [19] . Histone 3.3 lysine to methionine substitution (K36 M) reduces the methylation of lysine residue through inhibition of Su(var)3-9, Enhancer-of-zeste and Trithorax (SET) domain-containing enzymes [26] . This reduction in methylation at K36 was also observed in cell lines carrying the G34 V substitution [26] . Because V35_K36insL is an in-frame insertion and not a methionine substitution, further investigations will be necessary to elucidate any pathogenic mechanism of this in-frame insertion.
H3F3A/H3F3B driver mutations were described in giant cell tumour of the bone and chondroblastoma, which are considered benign tumours or benign but locally aggressive tumours, respectively [25, 27] , as well as in malignant giant cell tumour of the bone [28, 29] . A recent study by Amary et al [28] identified H3F3A G34 substitutions in 13 of 385 (3.37%) primary malignant bone tumours, classified as either osteosarcoma or malignant giant cell tumour of bone. In this study, we report recurrent H3F3A alterations in two of 14 (14.3%) UPSb tumours, a higher percentage than in previously reported malignant tumours, with the caveat of a smaller cohort size. Hence, the possibility of a malignant phenotype or evolution should be considered in tumours harbouring H3F3A alterations.
ATRX is a member of the SWI/SNF2 (SWItch/Sucrose Non-Fermentable) ATP-dependent chromatin remodelling protein complex [30] that regulates the expression of thousands of genes through remodelling of chromatin structure [31, 32] . ATRX has an established role in the carcinogenesis of multiple cancers, including gliomas [30] , small cell lung cancers [33] and six adult soft-tissue sarcomas (including UPS, leiomyosarcoma, dedifferentiated liposarcoma) [12] . Studies have demonstrated a regulatory role for ATRX, together with DAXX (death domain-associated protein) and other histone chaperone complex proteins, in the enrichment of histone H3.3 in telomeres and heterochromatin regions [34, 35] . Dysfunction ATRX/DAXX is associated with the alternative lengthening of telomeres, a phenomenon observed in 10-15% of cancers of mesenchymal origin (e.g. UPSb), resulting in widespread genomic destabilisation [36, 37] . In this study, we identified two missense mutations in ATRX: S2109I and E351V (COSMIC ID: COSM6608613) occurring in the helicase/ATPase conserved C-terminus and Enhancer zeste homologue 2 (EZH2) interacting region of the ATRX protein, respectively ( Figure 2C ). The helicase/ATPase subunit is the catalytic core of ATRX protein [38] which, together with other SNF2 proteins, is involved in ATP hydrolysis responsible for chromatin structural conformations [39] . The ATRX EZH2 interaction region is involved in the interaction of ATRX with polycomb repressive complex 2 (PRC2) protein complex, including the EZH2 catalytic subunit [40, 41] . Although further studies are required, mutations in these two functionally important domains can disrupt ATRX protein function, affecting the integrity of the chromatin structure. PRC2/EZH2 inhibitors are currently in clinical trials [40, 42] ; however, the complex and dual oncogenic and tumour-suppressing role of PRC2 in cancers requires detailed mechanistic insights before establishing the efficacy of these inhibitors [40] .
In the second part of this study we aimed to identify genome-wide gene fusions arising from chromosomal aberrations in eight UPSb tumour using RNA-Seq. A total of eight highly tumour-specific gene fusions were validated by RT-PCR, five of which were genomically characterised by LR-PCR. We identified two gene fusions previously reported in other cancers, CLTC-VMP1 and FARP1-STK24.
The CLTC-VMP1 gene fusion is identified in T13, lacking any WES alterations in TP53 or, H3F3A, ATRX, DOT1L chromatin remodelling genes. The cDNA breakpoint of CLTC identified here is different to those previously reported; however, the breakpoint position in VMP1 in UPSb is the same as reported for other tumours. The genomic interstitial deletion at 17q23.1 locus, revealed by genomic breakpoint analysis, leads to a complete deletion of the PTRH2 gene and a loss of six repeats of clathrin heavy chain/Vacuolar Protein Sorting (VPS) and four transmembrane helices of CLTC and VMP1, respectively ( Figure 3A) . The clathrin protein is involved in chromosome segregation and Golgi reassembly during mitosis and protein-protein interactions [43] . Rearrangements involving the CLTC-PTRH2-VMP1 locus have been observed in multiple tumour types, including glioblastoma, lung cancer, breast cancer and leukaemia [14] . VMP1 encodes an autophagy-related protein that promotes apoptosis in pancreatic cancer cells [44] . PTRH2 is a mitochondrial protein that induces apoptosis by regulation of the function of Groucho family transcriptional regulators [45] . Knockdown of PTRH2/BIT1 in adherent cells decreased cell survival and promoted staurosporine and serum-deprivation apoptosis of cells, consistent with the tumour suppressive role [46] . Altogether, and as Giacomini et al [14] suggested, the rearrangement involving CLTC-PTRH2-VMP1 and the CLTC-VMP1 gene fusion being out-of-frame are indicative of a disruption of the tumour suppressor activity.
The FARP1-STK24 gene fusion is formed by joining the two gene partners in opposing (sense-to-antisense) orientations, known as 5 ′ -to-5 ′ gene fusions ( Figure 3B) STK24 is a serine/threonine protein kinase belonging to the mammalian Sterile20-like (MST) kinase family, key signalling molecules that regulate the cell division cycle, cell morphogenesis, apoptosis and oncogenic transformation [48, 49] . A caspase-dependent apoptotic role has been identified for STK24 protein [50] . The STK24 protein is cleaved and activated by caspase-3 protein, through the STK24 regulatory domain, and translocated into the nucleus to promote apoptotic responses [48] . The loss of STK24 regulatory domain can subsequently interfere with STK24 activation and nuclear localisation. FARP1-STK24 forms an in-frame fusion protein with a potential constitutive activation of a kinase, a phenomenon observed in gene fusions exerting oncogenic functionality [51] . FARP1-STK24 may be associated with oncogenic properties, but further investigations are required. Gene fusions involving protein kinases are considered potential therapeutic targets. The use of kinase inhibitors in tumours harbouring kinase-related gene fusions can improve tumour prognosis and patient outcome [52] . For example, the efficacy of using ALK inhibitors in advanced nonsmall cell lung cancer with ALK rearrangement is evident in clinical trials [53] . A study by Olesen et al [54] Unsupervised clustering analysis of the RNA-Seq data clearly distinguished the UPSb samples from classical UPS, as well as synovial sarcomas and osteosarcomas. Supervised expression profiling of UPSb versus other tumour subtypes revealed elevated expression of FGF23, which was confirmed in four UPSb tumours using RT-qPCR. A study by Shiba et al [55] showed a highly specific immunohistochemical expression of FGF23 in phosphaturic mesenchymal tumours, whereas FGF23 expression was scored negative in 46 tumours, including osteosarcoma, chondrosarcoma and synovial sarcoma. Elevated expression of FGF23 can serve as a molecular biomarker specific to UPSb that can be diagnostically utilised in clinics. However, confirmation of elevated FGF23 expression in a larger UPSb cohort is recommended. The FGF family, comprised of signalling proteins, has a role in tissue repair and tumourigenesis, by regulating cell proliferation, migration and angiogenesis [56] . Promising curative results of a FGF23 monoclonal antibody drug, KRN23, was observed in patients with tumour-induced osteomalacia, a rare paraneoplastic syndrome clinically described by bone pain fractures and muscle weakness [57] . Further investigations are necessary to confirm an FGF23-targeted therapeutic opportunity in UPSb.
An enrichment of immune response gene expression was identified in UPSb, which has also been documented in other sarcomas, including UPSst [12] . The therapeutic benefit of pembrolizumab, an immune checkpoint inhibitor, has been documented in 40% of UPSst cases [58] . Although further investigations are needed, immune checkpoint inhibitors can be considered as a potential therapeutic option in UPSb patients.
In summary, this study provides the first detailed genetic and transcriptomic alterations landscape of UPSb tumours, thus providing useful insights into tumourigenesis and broadening the understanding of this tumour subtype. We identified novel recurrent gene mutations in multiple cancer-related genes, including chromatin remodelling genes, that are reported in UPSb tumours for the first time. We also identified novel and previously reported gene fusions. Several of the recurrently mutated genes and gene fusions represent potential druggable targets that can translate into clinics and improve patient prognosis. Elevated expression of FGF23 was identified, which may be a potential molecular biomarker for UPSb. Table S1 . Coding mutational rate of UPSb Table S2 . Summary of the individual recurrent mutations identified in TP53 and chromatin remodelling genes Table S3 . Somatic copy number alterations status of genes for which copy number alterations have been previously reported in UPSb and UPSst 
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